1	Preoperative COVID-19 Vaccination is Associated with Decreased Perioperative Mortality
2	after Major Vascular Surgery
3	Molly Ratner MD <sup>1*</sup> , Karan Garg MD <sup>1*</sup> , Heepeel Chang MD <sup>2</sup> , Anjali Nigalaye MD <sup>3</sup> , Steven
4	Medvedosky BS <sup>1</sup> , Glenn Jacobowitz MD <sup>1</sup> , Jeffrey J Siracuse MD <sup>4</sup> , Virendra Patel MD <sup>5</sup> , Marc
5	Schermerhorn MD <sup>6</sup> , Charles DiMaggio PhD <sup>1</sup> , Caron B Rockman MD <sup>1</sup>
6	
7	<sup>1</sup> Division of Vascular and Endovascular Surgery, Department of Surgery, New York University
8	Langone Medical Center, New York, NY.
9	<sup>2</sup> Division of Vascular Surgery, Department of Surgery, Westchester Medical Center, Valhalla,
10	NY.
11	<sup>3</sup> Division of Hospitalist Medicine, Department of Medicine, Mount Sinai Beth Israel Hospital,
12	New York, NY.
13	<sup>4</sup> Division of Vascular and Endovascular Surgery, Department of Surgery, Boston Medical
14	Center, Boston, Massachusetts
15	<sup>5</sup> Division of Vascular and Endovascular Interventions, Department of Surgery, New York
16	Presbyterian- Columbia University Irving Medical Center, New York, NY
17	<sup>6</sup> Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess
18	Medical Center, Boston, Massachusetts
19	
20	*Drs Molly Ratner and Karan Garg contributed equally to this manuscript.
21	
22	

23

24	Pre-publication Corresponding Author
25	Molly Ratner, MD
26	Division of Vascular and Endovascular Surgery
27	Department of Surgery
28	New York University Langone Medical Center, NYU Grossman
29	550 First Avenue, New York, NY 10016, USA
30	Phone: 212-263-7311
31	Molly.ratner@nyulangone.org
32	
33	Word Count: 4952
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

School of Medicine

47 Abstract

Background: The objective of this study was to examine the effect of COVID-19 vaccination
on perioperative outcomes after major vascular surgery.

50

51 Methods: This is a multicenter retrospective study of patients who underwent major vascular 52 surgery between December 2021 through August 2023. The primary outcome was all-cause 53 mortality within 30 days of index operation or prior to hospital discharge. Multivariable models 54 were used to examine the association between vaccination status and the primary outcome.

55

## 56 **Results:**

57 Of the total 85,424 patients included, 19161 (22.4%) were unvaccinated. Unvaccinated patients

were younger compared to vaccinated patients (mean age  $68.44 \pm 10.37$  years vs  $72.11 \pm 9.20$ 

59 years, p < .001) and less likely to have comorbid conditions, including hypertension (87.2% vs

60 89.7%, p <.001), congestive heart failure (14.5% vs 15.9%, p <.001), chronic obstructive

61 pulmonary disease (35.7% vs 36.3, p <.001) and renal failure requiring hemodialysis (1.4% vs

1.7%, p = .005). After risk factor adjustment, vaccination was associated with decreased

63 mortality (OR 0.7, 95% CI 0.62 - 0.81, p <.0001). Stratification by procedure type demonstrated

that vaccinated patients had decreased odds of mortality after open AAA (OR 0.6, 95% CI 0.42-

65 0.97, p = 0.03), EVAR (OR 0.6, 95% CI 0.43-0.83, p 0.002), CAS (OR 0.7, 95% CI 0.51-0.88, p

66 = 0.004) and infra-inguinal lower extremity interventions (OR 0.7, 95% CI 0.48-0.96, p = 0.03).

67

68 Conclusions:

69	COVID-19 vaccination is associated with reduced perioperative mortality in patients undergoing
70	vascular surgery. This association is most pronounced for patients undergoing aortic aneurysm
71	repair, carotid stenting and infrainguinal bypass.
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	

#### 92 Introduction

93 Although primarily an infection of the respiratory tract, Coronavirus Disease 2019 (COVID-19) generates a systemic inflammatory state leading to dysregulation of and injury to multiple organ 94 systems,<sup>1–5</sup> including the vasculature.<sup>6,7</sup> In the perioperative period, it has been proposed that the 95 96 exaggerated immune response elicited by both surgical trauma and severe acute respiratory 97 syndrome coronavirus 2 (SARS-CoV-2) may be responsible for the increased risk of perioperative mortality and morbidity in patients with active or recent infections.<sup>8,9</sup> These 98 findings have prompted groups like the American Society of Anesthesiologists to recommend 99 delaying elective surgery in patients with COVID-19.<sup>10</sup> However, as the pandemic enters a new 100 101 phase with widespread population immunity in the setting of vaccine development and/or prior 102 infection, risk stratification will need to reflect these changes. 103 104 COVID-19 vaccination has been associated with improved outcomes, including decreased 105 mortality, in patients undergoing various surgical procedures, such as cardiovascular, gastrointestinal operations and orthopedic surgeries.<sup>11–13</sup> However, there is a paucity of literature 106 107 evaluating the effect of COVID-19 vaccination on perioperative outcomes after major vascular 108 surgery, specifically. In this retrospective cohort study, we utilized the Society for Vascular 109 Surgery Vascular Quality Initiative (SVS-VQI) database to examine national trends in 110 perioperative mortality after major vascular surgery in the post-vaccination stage of the 111 pandemic.

112

113 Methods

114 Data Source

This study utilized the SVS-VQI, a prospectively maintained set of 14 registries containing
standardized data collected from over 1000 institutions across the United States, Canada and
Singapore. The VQI stores demographic, perioperative and postoperative data on major vascular
procedures for the purpose of improving surgical outcomes. Approval was obtained from the
SVS VQI Patient Safety Organization prior to analysis. The study was exempt from Institutional
Board Review approval and individual patient consent was waived given its retrospective
nature.

122

# **123** Study Population and Definitions

The SVS-VQI was queried from the start of COVID vaccination data collection on December
16<sup>th</sup>, 2021, through its termination on August 31, 2023. Patients were included if they underwent
a "major" vascular surgery procedure (i.e. those performed mainly in a non-ambulatory setting),
including aortic aneurysm repair (open vs endovascular abdominal/thoracic), carotid artery
endarterectomy or stenting and open peripheral revascularization. Endovascular peripheral
vascular interventions (PVI) were excluded given the shift towards performing these procedures
in an outpatient or ambulatory care setting.<sup>14</sup>

131

The primary variable of interest was COVID vaccination status. Vaccinated patients included those who had completed the full vaccine series by the time of surgery or had received at least one vaccine with the intention of completing the series. Baseline characteristics, such as demographic and medical history, were collected and included: age, sex, race, smoking status, hypertension, hyperlipidemia, diabetes, coronary artery disease (CAD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD), renal 138 failure requiring hemodialysis (HD) and preoperative medication utilization. The urgency of the

139 case (i.e. elective vs urgent/emergent) was additionally considered a potential confounder.

140

141 *Outcomes*:

142 The primary outcome was perioperative all-cause mortality, defined as occurring either prior to 143 discharge from the hospital or within 30 days of index operation. The secondary endpoints were 144 surgery-specific perioperative mortality.

145

146 *Statistical Analysis* 

147 All analyses were conducted in the R statistical software program. Comparisons of continuous 148 variables were based on t-tests and categorical variables were compared using Chi Square tests 149 as part of the CreatTableOne function of the R tableone package. Unadjusted odds ratios (ORs) 150 for the association of COVID vaccination with perioperative mortality were calculated using the 151 epitab function of the R epitools package. Separate multivariable logistic regression models for 152 each type of procedure (open repair, EVAR, TEVAR, carotid endarterectomy, carotid artery 153 stenting, infrainguinal and suprainguinal revascularization) comparing the association of COVID 154 vaccination with perioperative mortality were adjusted for confounding by age, gender, 155 hypertension, diabetes, race, ethnicity, pre-operative history of smoking and whether the 156 procedure was elective or urgent. A single model with an additional control variable for the type 157 of procedure was run for the full combined data. An additional multilevel model which set the 158 intercept to vary by procedure type was created to establish a baseline risk for mortality risk for 159 each procedure cohort. Results of the multivariable and multilevel models are presented as ORs 160 with associated p-values and 95% confidence intervals (CIs).

161 **Results** 

## **162** *Baseline Characteristics*

163 Of the total 85,424 patients identified, 19161 (22.4%) were unvaccinated at the time of index

- 164 operation. Unvaccinated patients were significantly younger compared to vaccinated patients
- 165 (mean age 68.44 + 10.37 years vs 72.11 + 9.20 years, p < 0.001). The majority of patients in

both cohorts were male (65.0% vs 65.6%, p = 0.34) and white, although black patients were

- 167 over-represented in the unvaccinated group (8.3% vs 7.6\%, p = 0.001). Unvaccinated patients
- were more likely to be current smokers (39.4% vs 25.5%, p <0.001) compared to vaccinated
- 169 patients. Unvaccinated patients were less likely to have a history of hypertension (87.2% vs

170 89.7%, p <0.001), CHF (14.5% vs 15.9%, p <0.001), COPD (35.7% vs 36.3, p <0.001) and HD

dependence (1.4% vs 1.7%, p = 0.005). Unvaccinated patients were additionally less likely to be

taking medications for cardiovascular risk reduction, including aspirin (75.2% vs 77.9%, p

173 <0.001), statins (77.9% vs 84.7%, p <0.001) and beta-blockers (44.9% vs 50.4%, p <0.001).

174 Unvaccinated patients were more likely to have a positive pre- or postoperative positive COVID

test, although the overall incidence was low (1.9% vs 1.1%, p <0.001). Unvaccinated patients

also less frequently underwent elective procedures (76.2% vs 83.5%, p <0.001). See Table I for a

177 full list of baseline characteristics.

178

#### 179 *Multivariable Model*

After adjusting for age, gender, race, ethnicity, smoking status, hypertension, diabetes, coronary
artery disease and dialysis, vaccinated status was associated with decreased mortality (OR 0.7,
95% CI 0.62 - 0.81, p <0.001). A multilevel model with the same variables in the multivariable</li>
logistic model with a random intercept by procedure type returned the same estimate for the

184 effect of the vaccine (OR 0.7, 95% CI 0.62 -0.81). After stratifying by procedure type,

- vaccinated patients had decreased odds of mortality after open AAA (OR 0.6, 95% CI 0.42-0.97,
- 186 p = 0.03), EVAR (OR 0.6, 95% CI 0.43-0.83, p= 0.002), CAS (OR 0.7, 95% CI 0.51-0.88, p =
- 187 0.004) and infra-inguinal lower extremity interventions (OR 0.7, 95% CI 0.48-0.96, p = 0.03).
- 188 However, vaccinated status did not significantly reduce the odds of perioperative death in
- 189 patients who underwent TEVAR, CEA or supra-inguinal lower extremity intervention. See
- 190 Figure 1 for the Forest Plot.
- 191

192 *Procedure Type:* 

**193** AORTIC SURGERY (TABLE II):

194 Similar to the overall cohort population, unvaccinated patients undergoing OAR, EVAR and 195 TEVAR were significantly younger than their vaccinated counterparts. Unlike the general 196 cohort, baseline comorbidities were similar between vaccinated and unvaccinated patients with a 197 few notable exceptions. Vaccinated patients who underwent TEVAR were more likely to have 198 preoperative diabetes (19.5% vs 15.3%, p = 0.002) and CAD (21.4% vs 18.1%, p = 0.02) 199 compared to the unvaccinated cohort. For all patients undergoing aortic surgery, vaccinated 200 patients were more likely to be on aspirin and statins. In this cohort, unvaccinated patients were 201 significantly less likely than vaccinated patients to undergo surgery electively. Vaccinated 202 patients who underwent OAR and EVAR were less likely to have a positive covid diagnosis 203 (0.9% vs 4.1%, p = 0.02; 1.4% vs 3.1%, p < 0.001) and perioperative mortality was significantly 204 lower compared to unvaccinated patients (7.1% vs 10.7%, p = 0.02; 3.1% vs 1.4%, p < 0.001). 205 There was no significant difference in covid status or perioperative mortality between 206 unvaccinated and vaccinated patients who underwent TEVAR.

207

# 208 Carotid Artery Revascularization (Table III)

209 Similar to the overall patient cohort, vaccinated patients undergoing CAS and CEA were more 210 likely to have a variety of medical comorbidities including hypertension, diabetes, and CHF. 211 Notably, however, they were less likely than unvaccinated patients to have a history of CVD 212 (54% vs 59.6%, p <0.001; 48.8% vs 55.2%, p <0.001). Vaccinated patients who underwent 213 carotid revascularization were more likely to be on an aspirin, statin, ACE-inhibitor, or beta-214 blocker. Vaccinated patients who underwent CAS were less likely to have a positive covid 215 diagnosis (1.0% vs 1.6%, p < .001) and peri-operative mortality was significantly reduced 216 compared to the unvaccinated cohort (0.7% vs 1.3%, p < 0.001). There was no significant 217 difference in covid status or perioperative mortality between unvaccinated and vaccinated 218 patients who underwent CEA.

219

220 Peripheral Revascularization (Table IV)

221 Unlike the overall study population or patients undergoing infra-inguinal bypass, white patients 222 were over-represented in the unvaccinated cohort who underwent supra-inguinal bypass (82.9% 223 vs 75.2%, p <0.001). Vaccinated patients who underwent peripheral revascularization were more 224 likely to have a history of HTN, diabetes, and HD and to be on ACE-inhibitors or beta-blockers. 225 In patients undergoing supra-inguinal bypass, there was no significant difference in the 226 likelihood of undergoing an elective procedure between vaccinated and unvaccinated patients. 227 In patients with underwent either supra- or infrainguinal bypass, there was no significant 228 difference in the proportion of vaccinated and unvaccinated patients with a positive COVID 229 diagnosis and there was no significant difference in perioperative mortality.

#### 230 Discussion

231 In this retrospective analysis of a large, multicenter database, vaccination against COVID was 232 significantly associated with reduced perioperative mortality after major vascular surgery. 233 Despite presenting with a high burden of comorbid conditions, including hypertension, diabetes 234 and coronary artery disease, vaccinated patients had reduced odds of perioperative mortality after 235 open AAA, EVAR, CAS, and infra-inguinal lower extremity open revascularization procedures. 236 Our results underscore the efficacy of the COVID vaccination in reducing perioperative all-cause 237 mortality, particularly in older, high-risk patients. 238 239 Recently published reports have examined the protective effect of COVID vaccination amongst a

240 different subset of surgical patients. In a retrospective, multicenter cohort review of patients 241 undergoing high risk surgery, Sharath et al found that the unadjusted and adjusted 90-day 242 mortality rates between vaccinated patients with and without a recent COVID-19 diagnosis were 243 comparable. Moreover, in a subgroup analysis of matched vaccinated and unvaccinated COVID positive patients, vaccination reduced 90-day mortality by close to 50%.<sup>15</sup> In a second. 244 245 retrospective study of cardiac surgery patients, a cohort with similar risk factors to those 246 undergoing vascular surgery, Blumenfeld et al examined the effect of perioperative COVID-19 247 infection on 30-day mortality before and after the development of the COVID vaccine. The 248 authors reported a significantly elevated risk of perioperative mortality in COVID-19 positive 249 patients prior to vaccine availability. However, after universal vaccination protocols were put in 250 place, the association between COVID-19 infection and increased perioperative mortality was no longer apparent.<sup>16</sup> Although further research is needed, it has been proposed that the reduced 251

11

254

255 The reduced all-cause mortality seen in our study population of largely COVID negative patients 256 cannot be fully explained by the effectiveness of the vaccine in preventing COVID-19-related 257 deaths. A similar reduction in all-cause mortality was observed in a population-based study out 258 of Australia, in which the authors proposed several possible explanations for this finding, 259 including indirect reduction in outcomes associated with COVID-19 infection, such as cardiovascular and pulmonary complications.<sup>17</sup> Given that vascular surgery patients are amongst 260 the highest risk patients for postoperative cardiac complications,<sup>18</sup> this hypothesis seems 261 262 reasonable. An additional consideration brought forth by the authors was the effect of 263 confounding, particularly in the form of behavioral differences such as the healthy vaccinee effect.<sup>17</sup> However, it is worth nothing that vaccinated patients within our study tended to present 264 265 with more serious comorbid conditions which we believe reduces the likelihood that vaccination 266 status is a simply a marker for access to and trust in the health care system.

267

The higher proportion of older and sicker patients who were vaccinated in our study is consistent with epidemiologic data within the United States. In the 2021, United States Census Bureau's Household Pulse Survey of around 61,000 people, unvaccinated people were generally younger with 75% of the unvaccinated population under the age of 50.<sup>19</sup> This pattern of vaccination can be at least partially attributed to the way the COVID vaccine was rolled out in most states with priority given to older adults and those living in group living facilities. However, beyond logistics, it is conceivable to believe that patients who are aware of serious comorbid conditions

275 may be more likely to vaccinate for specifically that reason, given the widespread knowledge 276 that people with these risk factors generally had worse outcomes with COVID infections. In fact, 277 studies have described the relationship between increasing age or pre-existing medical conditions and the intention to vaccinate.<sup>20–22</sup>The US Census Survey additionally reported a higher 278 279 representation of non-Hispanic Black people within the unvaccinated cohort compared to the vaccinated cohort (13% vs 11%),<sup>19</sup> a finding mirrored within our own study population. The 280 281 significance of this disparity cannot be understated, particularly given the disproportionate impact of both COVID 19 and atherosclerotic cardiovascular disease on black individuals.<sup>23</sup> A 282 more comprehensive understanding of what drives vaccine hesitancy amongst vascular surgery 283 284 patients should be undertaken to better address this issue.

285

286 During the height of the pandemic, major society guidelines suggested deferring elective procedures for several weeks after COVID-19 infection.<sup>10</sup> However, in the endemic phase of 287 288 COVID-19, as more patients have been exposed to the virus through infection and immunization, 289 guidelines around surgical timing are in flux. The results of our study, in conjunction with others,<sup>15,24</sup> suggests a protective effect of vaccination prior to surgery, particularly in patients 290 291 whose risk factors predispose them to needing surgical intervention in urgent or emergent 292 settings, such as those with vascular disease. However, further studies are needed to discern 293 optimal timing between vaccination and operative intervention to provide greatest protection. 294 295 There are several limitations to this study, including its retrospective observational nature. While

the use of the VQI-SVS database allowed us to capture a broader population, however, the

297 registry lacks granular detail. For instance, the extent of vascular disease with regards to anatomy

298 and morphology cannot be fully categorized. Furthermore, while data input is standardized, the 299 accuracy and completeness of the information is center specific. Certain variables, including the 300 length of time between vaccination and surgery, choice of vaccination, and implementation of 301 booster shots were not consistently input into the database, limiting the extent of the analysis we 302 were able to perform. Furthermore, the VOI does not generate data on the specific cause of 303 death, so analysis was limited to all-cause mortality. Successful recovery from COVID infection 304 confers a degree of immunity and it is unclear whether prior infection provides a synergetic, 305 reductive, or independent effect on vaccination protection against perioperative mortality. 306 Further longitudinal studies will be needed to elucidate these relationships. 307 308 **CONCLUSION:** 309 In our analysis of the Vascular Quality Initiative (VQI) database of all patients undergoing major 310 vascular interventions, we found an association between vaccination status and improved

311 perioperative survival. This association was most pronounced for patients undergoing AAA

312 repair, carotid stenting and infrainguinal bypass. As the pandemic enters the endemic stage,

313 future studies must focus on not only the prevention of viral infection in high-risk surgical

314 patients, but also on downstream benefits that vaccines may impart on society.

315

316 Acknowledgements: None

317 Funding: None

318 Disclosures: None

319

320

## 321 **REFERENCES**

- 322 1. Inciardi RM, Solomon SD, Ridker PM, Metra M. Coronavirus 2019 Disease (COVID-19),
- 323 Systemic Inflammation, and Cardiovascular Disease. *JAHA*. 2020;9(16):e017756.
- doi:10.1161/JAHA.120.017756
- 325 2. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19.

326 *Am J Emerg Med.* 2020;38(7):1504-1507. doi:10.1016/j.ajem.2020.04.048

- 327 3. Janardhan V, Janardhan V, Kalousek V. COVID-19 as a Blood Clotting Disorder
- 328 Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic
- 329 Implications for Stroke Thrombectomy. *J Neuroimaging*. 2020;30(5):555-561.

doi:10.1111/jon.12770

- 4. Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC. Incidence of acute kidney injury
  in COVID-19 infection: a systematic review and meta-analysis. *Crit Care*. 2020;24(1):346.
- doi:10.1186/s13054-020-03009-y
- Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver
  involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2020;5(7):667-678. doi:10.1016/S2468-1253(20)30126-6
- 337 6. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients
- 338 with COVID-19. *Lancet Haematol*. 2020;7(6):e438-e440. doi:10.1016/S2352-
- 339 3026(20)30145-9

340	7.	Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in
341		hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002.
342		doi:10.1111/jth.14888
343	8.	COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing
344		surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet.
345		2020;396(10243):27-38. doi:10.1016/S0140-6736(20)31182-X
346	9.	Doglietto F, Vezzoli M, Gheza F, et al. Factors Associated With Surgical Mortality and
347		Complications Among Patients With and Without Coronavirus Disease 2019 (COVID-19) in
348		Italy. JAMA Surg. 2020;155(8):691-702. doi:10.1001/jamasurg.2020.2713
349	10.	Anesthesia Patient Safety Foundation. American Society of Anesthesiologists and
350		Anesthesia Patient Safety Foundation joint statement on elective surgery and anesthesia for
351		patients after COVID-19 infection. Accessed January 20, 2024. https://www.apsf.org/news-
352		updates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-after-
353		covid-19-infection/
354	11.	Jagadeesh N, Gnany J, Kapadi S, Koshy N, Shaw D. COVID-19 Vaccination: Does It Alter
355		Postoperative Mortality and Morbidity in Hip Fractures? Cureus. 2022;14(12):e32688.
356		doi:10.7759/cureus.32688
357	12.	Prasad NK, Lake R, Englum BR, et al. COVID-19 Vaccination Associated With Reduced
358		Postoperative SARS-CoV-2 Infection and Morbidity. Annals of Surgery. 2022;275(1):31-36.
359		doi:10.1097/SLA.00000000005176

360	13. Prasad NK, Englum BR, Mayorga-Carlin M, et al. Partial COVID-19 vaccination associated
361	with reduction in postoperative mortality and SARS-CoV-2 infection. Am J Surg.
362	2022;224(4):1097-1102. doi:10.1016/j.amjsurg.2022.03.038
363	14. Mesbah Oskui P, Kloner RA, Burstein S, et al. The safety and efficacy of peripheral vascular
364	procedures performed in the outpatient setting. J Invasive Cardiol. 2015;27(5):243-249.
365	15. Sharath SE, Kougias P, Daviú-Molinari T, Faridmoayer E, Berger DH. Association Between
366	Coronavirus Disease 2019 Vaccination and Mortality After Major Operations. Annals of
367	Surgery. 2024;279(1):58-64. doi:10.1097/SLA.0000000000006051
368	16. Blumenfeld O, Rosenberg A, Reuven M, Caspi I, Sharoni E, Leviner DB. The effect of
369	COVID-19 vaccination on 30-day mortality after cardiac surgery – Insights from the Israel
370	national registries. Infection Prevention in Practice. 2024;6(1):100334.
371	doi:10.1016/j.infpip.2023.100334
372	17. Liu B, Stepien S, Dobbins T, et al. Effectiveness of COVID-19 vaccination against COVID-
373	19 specific and all-cause mortality in older Australians: a population based study. The Lancet
374	Regional Health - Western Pacific. 2023;40:100928. doi:10.1016/j.lanwpc.2023.100928
375	18. Beaulieu RJ, Sutzko DC, Albright J, Jeruzal E, Osborne NH, Henke PK. Association of High
376	Mortality With Postoperative Myocardial Infarction After Major Vascular Surgery Despite
377	Use of Evidence-Based Therapies. JAMA Surg. 2020;155(2):131.
378	doi:10.1001/jamasurg.2019.4908

379	19. US Bureau of Census. Household Pulse Survey Data. Published online 2021. Accessed
380	January 1, 2024. https://www.census.gov/programs-surveys/household-pulse-
381	survey/data.html
382	20. Daly M, Robinson E. Willingness to Vaccinate Against COVID-19 in the U.S.:
383	Representative Longitudinal Evidence From April to October 2020. American Journal of
384	Preventive Medicine. 2021;60(6):766-773. doi:10.1016/j.amepre.2021.01.008
385	21. Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: Results of a
386	nationwide survey. Vaccine. 2021;39(7):1080-1086. doi:10.1016/j.vaccine.2021.01.010
387	22. Trent M, Seale H, Chughtai AA, Salmon D, MacIntyre CR. Trust in government, intention to
388	vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the
389	United States, United Kingdom, and Australia. Vaccine. 2022;40(17):2498-2505.
390	doi:10.1016/j.vaccine.2021.06.048
391	23. Carnethon MR, Pu J, Howard G, et al. Cardiovascular Health in African Americans: A
392	Scientific Statement From the American Heart Association. Circulation. 2017;136(21).
393	doi:10.1161/CIR.000000000000534
394	24. Le ST, Kipnis P, Cohn B, Liu VX. COVID-19 Vaccination and the Timing of Surgery
395	Following COVID-19 Infection. Annals of Surgery. 2022;276(5):e265-e272.
396	doi:10.1097/SLA.00000000005597
397	

	Unvaccinated (n = 19161)	Vaccinated ( $n = 66263$ )	P Value
Age (mean +/- SD)	68.44 +/- 10.37	72.11 +/- 9.20	<0.001
Male	12461 (65.0%)	43479 (65.6%)	0.14
Race			
White	16191 (84.5%)	56359 (85.1%)	0.06
Black	1584 (8.3%)	5009 (7.6%)	.001
Current Smoker	7245 (37.8%)	16896 (25.5%)	<0.001
Former Smoker	7260 (37.9%)	33248 (50.2%)	<.001
Hypertension	16700 (87.2%)	59442 (89.7%)	<0.001
Diabetes	6957 (36.3%)	24225 (36.5%)	0.53
CAD	6422 (33.5%)	22601 (34.1%)	0.13
CABG	2944 (15.4%)	11438 (17.3%)	<0.001
PCI	4217 (22.0%)	15381 (23.2%)	0.001

Table I: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing major vascular surgery

CHF	2771 (14.5%)	10523 (15.9%)	<0.001	
COPD	5423 (35.7%)	17633 (36.3%)	<0.001	
Hemodialysis	270 (1.4%)	1129 (1.7%)	0.005	
Preoperative Medication	S			
Aspirin	14413 (75.2%)	51610 (77.9%)	<0.001	
Statin	14925 (77.9%)	56021 (84.7%)	<0.001	
ACE inhibitor	9546 (49.8%)	35075 (53.0%)	<0.001	
P2Y <sub>12</sub> -Inhibitor	9470 (49.4%)	32123 (48.5%)	0.02	
Anticoagulation	2511 (13.1%)	9698 (14.6%)	<0.001	
Beta Blocker	8606 (44.9%)	33354 (50.4%)	<0.001	
Elective Status	14593 (76.2%)	55252 (83.5%)	<0.001	
Positive COVID Status	358 (1.9%)	734 (1.1%)	<0.001	
Perioperative Mortality	360 (1.8%)	761 (1.1%)	<0.001	

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACE-inhibitor, angiotensin converting enzyme inhibitor Bold faced p values indicate significance.

		OPEN			EVAR			TEVAR	
Variable	Unvaccinated (n= 394)	Vaccinated (n = 1559)	P value	Unvaccinated (n= 2149)	Vaccinated (n= 8970)	P value	Unvaccinated (n = 1075)	Vaccinated (n = 3404)	P value
Age (mean +/- SD)	67.29 +/- 9.22	69.90 +/- 8.38	<0.001	71.76 +/- 9.08	74.28 +/- 8.38	<0.001	65.64 +/- 13.30	70.91 +/- 11.11	<0.001
Male	283 (71.8%)	1179 (75.6%)	0.14	1709 (79.5%)	7214 (80.5)	0.60	711 (66.1%)	2250 (66.1)	0.73
Race									
White	331 (84.0%)	1204 (77.3%)	0.004	151 (7.0%)	563 (6.3%)	.20	674 (62.7%)	2360 (69.4%)	<0.001
Black	22 (5.6%)	78 (5.0%%)	0.64	1801 (83.9%)	7539 (84.1%)	.85	242 (22.5%)	535 (15.7%)	<0.001
Current Smoker	147 (37.4%)	757 (48.7%)	<0.001	939 (43.8%)	2673 (29.8%)	<0.001	432 (40.3%)	978 (28.8%)	<0.001
Former Smoker	204 (51.9%)	630 (40.5%)	<0.001	909 (42.4%)	4985 (55.6%)	<0.001	380 (35.4%)	1664 (48.9%)	<0.001

Table II: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing aortic surgery

Hypertension	318 (80.7%)	1305 (83.8%)	0.16	1794 (83.5%)	7698 (85.9%)	0.005	979 (91.2%)	3099 (91.1%)	0.98
Diabetes	64 (16.2%)	271 (17.4%)	0.64	442 (20.6%)	1924 (21.5%)	0.38	164 (15.3%)	665 (19.5%)	0.002
CAD	82 (20.8%)	348 (22.4%)	0.54	574 (26.7%)	2509 (28.0%)	0.24	195 (18.1%)	727 (21.4%)	0.02
Prior CABG	43 (10.9%)	174 (11.2%)	0.95	297 (13.8%)	1328 (14.8%)	0.26	93 (8.7%)	400 (11.8%)	0.006
Prior PCI	67 (17.0%)	290 (18.6%)	0.50	478 (22.3%)	2048 (22.9%)	0.59	147 (13.7%)	576 (16.9%)	0.01
CHF	33 (8.4%)	156 (10.0%)	0.37	304 (14.2%)	1319 (14.7%)	0.53	190 (17.7%)	574 (16.9%)	0.57
COPD	128 (32.5%)	524 (33.7%)	0.71	747 (34.8%)	3096 (34.5%)	0.86	352 (32.7%)	1157 (34.0%)	0.47
Hemodialysis	2 (0.5%)	8 (0.5%)	1.00	27 (1.3%)	96 (1.1%)	0.53	30 (2.8%)	91 (2.7%)	0.92
Preop									
Medications									
Aspirin	207 (52.7%)	923 (59.4%)	0.02	1207 (56.2%)	5255 (58.7%)	0.04	575 (53.5%)	2015 (59.3%)	0.001
Statins	242 (61.6%)	1193 (76.7%)	<0.001	1415 (65.9%)	6822 (76.2%)	<0.001	618 (57.5%)	2416	<0.001

								(71.1%)	
ACE- inhibitor	152 (38.7%)	738 (47.4%)	0.002	975 (45.4%)	4310 (48.1%)	0.02	488 (45.4%)	1561 (45.9%)	0.82
P2Y <sub>12</sub> inhibitors	32 (8.1%)	126 (8.1%)	1.00	333 (15.5%)	1195 (13.3%)	0.01	144 (13.4%)	406 (11.9%)	0.22
Anticoagulati on	37 (9.4%)	206 (13.2%)	0.05	337 (15.7%)	1572 (17.5%)	0.04	163 (15.2%)	630 (18.5%)	0.01
Beta- blocker	168 (42.9%)	760 (48.8%)	0.04	1004 (46.8%)	4555 (50.8%)	0.001	730 (67.9%)	2248 (66.0%)	0.27
Elective	281 (71.3%)	1210 (77.6%)	0.01	1631 (76.2%)	7787 (86.9%)	<0.001	706 (65.7%)	2694 (79.2%)	<0.001
Positive COVID Status	16 (4.1%)	14 (0.9%)	<0.001	41 (1.9%)	103 (1.2%)	0.005	26 (2.4%)	58 (1.7%)	0.13
Mortality	42 (10.7%)	111 (7.1%)	0.02	67 (3.1%)	127 (1.4%)	<0.001	57 (5.3%)	141 (4.2%)	0.11

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Table III: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing carotid artery

revascularization

		CAS		CEA				
Variable	Unvaccinated	Vaccinated.	P value	Unvaccinated	Vaccinated	P Value		
	(n = 6933)	(n = 22308)	i value	(n = 5790)	(n = 20506)	i value		
Age (mean +/- SD)	<b>69.83</b> +/-	73.16 +/- 8.98	<0.001	69.07 + /- 9.53	72.02 1/ 8.61	<0.001		
Age (mean +/- SD)	10.18	/3.10 +/- 0.70	<0.001	07.07 + /- 7.33	/2.02 +/- 0.01	<0.001		
Male	4306 (62.1%)	14008 (62.8%)	0.30	3509 (60.6%)	12288 (59.9%)	0.58		
Race								
White	6075 (87.7%)	19881 (89.1%)	0.001	5157 (89.1%)	18331 (89.5%)	0.42		
Black	442 (6.4%)	1270 (5.7%)	0.04	280 (4.8%)	1065 (5.2%)	0.27		
Current Smoker	2245 (32.5%)	4481 (20.1%)	<0.001	1915 (33.1%)	4515 (22.0%)	<0.001		
Former Smoker	2660 (38.5%)	11152 (50.0%)	<0.001	2265 (39.1%)	10194 (49.7%)	<0.001		
Hypertension	6089 (87.9%)	20235 (90.7%)	<0.001	5161 (89.1%)	18604 (90.8%)	<0.001		
Diabetes	2585 (37.3%)	8826 (39.6%)	0.001	2110 (36.4%)	7911 (38.6%)	<0.001		
CAD	3141 (45.3%)	10805 (48.5%)	<0.001	1618 (27.9%)	5527 (27.0%)	0.15		

Prior CABG	1126 (16.3%)	4233 (19.0%)	<0.001	958 (16.6%)	3604 (17.6%)	0.07
Prior PCI	1659 (24.0%)	5826 (26.2%)	<0.001	1239 (21.4%)	4506 (22.0%)	0.35
CHF	1038 (15.0%)	3759 (16.9%)	<0.001	710 (12.3%)	2781 (13.6%)	0.01
COPD	1636 (23.6%)	5282 (23.7%)	0.89	1343 (23.2%)	4696 (22.9%)	0.66
CVD	4127 (59.6%)	12031 (54.0%)	<0.001	3196 (55.2%)	9997 (48.8%)	<0.001
Hemodialysis	89 (1.3%)	286 (1.3%)	1.00	48 (0.8%)	217 (1.1%)	0.14
Preoperative						
Medications						
Aspirin	5745 (82.9%)	19499 (87.5%)	<0.001	4707 (81.4%)	17086(83.4%)	<0.001
Statin	5721 (82.6%)	19679 (88.3%)	<0.001	4757 (82.2%)	18066(88.2%)	<0.001
ACE-inhibitor	3483 (50.3%)	12064 (54.1%)	<0.001	3057 (52.8%)	11287 (55.1%)	0.002
P2Y <sub>12</sub> -inhibitor	5522 (79.7%)	19057 (85.5%)	<0.001	2459 (42.5%)	8320 (40.6%)	0.01
Anticoagulation	409 (6.4%)	1463 (7.3%)	0.02	784 (13.5%)	3091 (15.1%)	0.004
Beta-blocker	3085 (44.5%)	11207 (50.3%)	<0.001	2448 (42.3%)	9815 (47.9%)	<0.001
Elective	5201 (75.1%)	18367 (82.5%)	<0.001	4696 (81.1%)	17845 (87.0%)	<0.001
Positive COVID	114 (1.6%)	216 (1.0%)	<.001	110 (1.2%)	208 (1.0%)	.20

Status						
Mortality	88 (1.3%)	157 (0.7%)	<.001	22 (0.4%)	62 (0.3%)	.36

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart

failure; CVD, cerebrovascular disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Table IV: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing revascularization for

peripheral artery disease.

		SUPRAINGUINAL			INFRAINGUINAL	
	Unvaccinated	Vaccinated	P Value	Unvaccinated	Vaccinated	P Value
	(N = 620)	(N = 1635)	r value	(n = 2200)	(n = 7881)	r value
Age (mean +/- SD)	62.15 +/- 9.866	66.81 +/- 9.682	<0.001	64.90 +/-10.412	68.87 +/- 9.928	<0.001
Male	383 (61.8%)	957 (58.5%)	0.32	1560 (70.9%)	5584 (70.9%)	0.87
Race						0.10
White	513 (82.9%)	1228 (75.2%)	<0.001	1640 (74.5%)	5816 (73.8%)	0.51
Black	65 (10.5%)	190 (11.6%)	0.45	382 (17.4%)	1308 (16.6%)	0.40
Current Smoker	407 (65.6%)	816 (49.9%)	<0.001	1160 (52.8%)	2804 (35.6%)	<0.001
Former Smoker	192 (31.0%)	745 (45.6%)	<0.001	710 (32.3%)	3751 (47.6%)	<0.001
Hypertension	502 (81.1%)	1393 (85.3%)	0.02	1857 (84.5%)	7108 (90.2%)	<0.001
Diabetes	164 (26.5%)	526 (32.2%)	0.01	1068 (48.6%)	4102 (52.1%)	0.01
CAD	158 (25.5%)	402 (24.7%)	0.68	654 (31.3%)	2283 (30.5%)	0.49
Prior CABG	56 (9.0%)	209 (12.8%)	0.01	371 (16.9%)	1490 (18.9%)	0.03

Prior PCI	109 (17.6%)	285 (17.4%)	0.94	518 (23.6%)	1850 (23.5%)	0.94
CHF	67 (10.8%)	219 (13.4%)	0.10	429 (19.5%)	1715 (21.8%)	0.02
COPD	208 (33.5%)	644 (39.4%)	0.01	619 (28.2%)	2234 (28.4%)	0.87
Hemodialysis	5 (0.8%)	38 (2.3%)	0.02	<b>69 (3.1%)</b>	393 (5.0%)	<0.001
Preoperative						
Medications						
Aspirin	445 (71.9%)	1177 (72.0%)	0.96	1527 (69.4%)	5655 (71.8%)	0.03
Statin	485 (78.4%)	1319 (80.7%)	0.22	1687 (76.8%)	6526 (82.9%)	<0.001
ACE-inhibitor	279 (45.1%)	831 (50.8%)	0.02	1112 (50.6%)	4284 (54.4%)	0.002
P2Y <sub>12</sub> -inhibitor	154 (24.9%)	354 (21.7%)	0.10	826 (37.6%)	2665 (33.8%)	0.001
AC	140 (22.6%)	343 (22.0%)	0.40	641 (29.1%)	2393 (30.4%)	0.27
Beta-blocker	222 (35.9%)	687 (42.0%)	0.01	949 (43.2%)	4082 (51.8%)	<0.001
Elective	461 (74.5%)	1259 (77.1%)	0.20	1617 (73.6%)	6090 (77.3%)	<0.001
Positive COVID Status	10 (1.6%)	21 (1.3%)	0.55	41 (1.9%)	114 (1.4%)	0.16
Mortality	25 (4.0%)	59 (3.6%)	0.64	34 (1.5%)	104 (1.3%)	0.42

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; CVD, cerebrovascular disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.




Figure 1: Forest Plot Evaluating COVID Vaccination Status and Mortality